11 research outputs found
Recommended from our members
Secretory Mechanisms of aP2: an Adipokine Integrating Adipose Depots with Metabolism
Adipose Fatty Acid Binding Protein 4 (FABP4) or aP2, plays an important role in several immunometabolic pathologies such as type 2 diabetes, atherosclerosis, fatty liver disease, asthma, and cancer. Long considered to be a cytosolic protein, aP2 has recently been detected in conditioned media of adipocytes. Interestingly, there is a growing body of literature showing association of increased circulating levels of aP2 with cardiovascular disease and metabolic syndrome. Our lab has discovered a role for aP2 secreted from adipocytes in regulating liver glucose output and blood glucose levels in diabetes. The emerging biology of this novel adipokine makes it critical to understand the route and mechanisms that lead to its secretion
Sympathetic tone dictates the impact of lipolysis on FABP4 secretion
Levels of circulating fatty acid binding protein 4 (FABP4) protein are strongly associated with obesity and metabolic disease in both mice and humans, and secretion is stimulated by ÎČ-adrenergic stimulation both in vivo and in vitro. Previously, lipolysis-induced FABP4 secretion was found to be significantly reduced upon pharmacological inhibition of adipose triglyceride lipase (ATGL) and was absent from adipose tissue explants from mice specifically lacking ATGL in their adipocytes (ATGLAdpKO). Here, we find that upon activation of ÎČ-adrenergic receptors in vivo, ATGLAdpKO mice unexpectedly exhibited significantly higher levels of circulating FABP4 as compared with ATGLfl/fl controls, despite no corresponding induction of lipolysis. We generated an additional model with adipocyte-specific deletion of both FABP4 and ATGL (ATGL/FABP4AdpKO) to evaluate the cellular source of this circulating FABP4. In these animals, there was no evidence of lipolysis-induced FABP4 secretion, indicating that the source of elevated FABP4 levels in ATGLAdpKO mice was indeed from the adipocytes. ATGLAdpKO mice exhibited significantly elevated corticosterone levels, which positively correlated with plasma FABP4 levels. Pharmacological inhibition of sympathetic signaling during lipolysis using hexamethonium or housing mice at thermoneutrality to chronically reduce sympathetic tone significantly reduced FABP4 secretion in ATGLAdpKO mice compared with controls. Therefore, activity of a key enzymatic step of lipolysis mediated by ATGL, per se, is not required for in vivo stimulation of FABP4 secretion from adipocytes, which can be induced through sympathetic signaling
Recommended from our members
Discovery of FAHFA-Containing Triacylglycerols and Their Metabolic Regulation
FAHFAs are a class of bioactive lipids, which show great promise for treating diabetes and inflammatory diseases. Deciphering the metabolic pathways that regulate endogenous FAHFA levels is critical for developing diagnostic and therapeutic strategies. However, it remains unclear how FAHFAs are metabolized in cells or tissues. Here, we investigate whether FAHFAs can be incorporated into other lipid classes and identify a novel class of endogenous lipids, FAHFA-containing triacylglycerols (FAHFA-TGs), which contain a FAHFA group esterified to the glycerol backbone. Isotope-labeled FAHFAs are incorporated into FAHFA-TGs when added to differentiated adipocytes, which implies the existence of enzymes and metabolic pathways capable of synthesizing these lipids. Induction of lipolysis (i.e., triacylglycerol hydrolysis) in adipocytes is associated with marked increases in nonesterified FAHFA levels, demonstrating that FAHFA-TGs breakdown is a regulator of cellular FAHFA levels. To quantify FAHFA levels in FAHFA-TGs and determine their regioisomeric distributions, we developed a mild alkaline hydrolysis method that liberates FAHFAs from triacylglycerols for easier detection. FAHFA-TG concentrations are greater than 100-fold than that of nonesterified FAHFAs, indicating that FAHFA-TGs are a major reservoir of FAHFAs in cells and tissues. The discovery of FAHFA-TGs reveals a new branch of TG and FAHFA metabolism with potential roles in metabolic health and regulation of inflammation
Faster Protocol for Endogenous Fatty Acid Esters of Hydroxy Fatty Acid (FAHFA) Measurements
Fatty acid esters of hydroxy fatty acids (FAHFAs) are a recently discovered class of endogenous lipids with antidiabetic and anti-inflammatory activities. Interest in these lipids is due to their unique biological activites and the observation that insulin-resistant people have lower palmitic acid esters of hydroxystearic acid (PAHSA) levels, suggesting that a FAHFA deficiency may contribute to metabolic disease. Rigorous testing of this hypothesis will require the measurement of many clinical samples; however, current analytical workflows are too slow to enable samples to be analyzed quickly. Here we describe the development of a significantly faster workflow to measure FAHFAs that optimizes the fractionation and chromatography of these lipids. We can measure FAHFAs in 30 min with this new protocol versus 90 min using the older protocol with comparable performance in regioisomer detection and quantitation. We also discovered through this optimization that oleic acid esters of hydroxystearic acids (OAHSAs), another family of FAHFAs, have a much lower background signal than PAHSAs, which makes them easier to measure. Our faster workflow was able to quantify changes in PAHSAs and OAHSAs in mouse tissues and human plasma, highlighting the potential of this protocol for basic and clinical applications
Faster Protocol for Endogenous Fatty Acid Esters of Hydroxy Fatty Acid (FAHFA) Measurements
Fatty
acid esters of hydroxy fatty acids (FAHFAs) are a recently
discovered class of endogenous lipids with antidiabetic and anti-inflammatory
activities. Interest in these lipids is due to their unique biological
activites and the observation that insulin-resistant people have lower
palmitic acid esters of hydroxystearic acid (PAHSA) levels, suggesting
that a FAHFA deficiency may contribute to metabolic disease. Rigorous
testing of this hypothesis will require the measurement of many clinical
samples; however, current analytical workflows are too slow to enable
samples to be analyzed quickly. Here we describe the development of
a significantly faster workflow to measure FAHFAs that optimizes the
fractionation and chromatography of these lipids. We can measure FAHFAs
in 30 min with this new protocol versus 90 min using the older protocol
with comparable performance in regioisomer detection and quantitation.
We also discovered through this optimization that oleic acid esters
of hydroxystearic acids (OAHSAs), another family of FAHFAs, have a
much lower background signal than PAHSAs, which makes them easier
to measure. Our faster workflow was able to quantify changes in PAHSAs
and OAHSAs in mouse tissues and human plasma, highlighting the potential
of this protocol for basic and clinical applications
Role of AIG1 and ADTRP in Endogenous FAHFA Regulation
Androgenâinduced gene 1 (AIG1) and Androgenâdependent TFPIâregulating protein (ADTRP) are atypical transmembrane hydrolases that rely on a catalytic threonine for their enzymatic activity. In vitro characterization of AIG1 and ADTRP in lysates and cells identified fatty acid ester of hydroxy fatty acids (FAHFAs) as their putative substrates. Here, we generate ADTRP knockout (AdtrpâKO), AIG1 knockout (Aig1âKO), and ADTRP/AIG1 double deficient (DKO) mice using CRISPRâCas9 technology to test whether these enzymes regulate FAHFAs in vivo. AIG1, ADTRP, or a deficiency in both enzymes leads to decreased FAHFA hydrolytic activity in tissue lysates. Quantitative measurement of FAHFA levels in several tissues revealed increased FAHFA levels in brown adipose tissue (BAT), subcutaneous adipose tissue (SQWAT), and perigonadal WAT (PGWAT) of AdtrpâKO mice consistent with the loss of FAHFA degrading activity. Furthermore, contribution by AIG1 was modest and only observed in the kidney and BAT of DKO mice. Lipidomics of tissues from knockout and wild type control mice detected no significant changes in other lipid classes to indicate that these enzymes are specific for FAHFA substrates. Furthermore, we developed a potent and selective, dual AIG1/ADTRP inhibitor to enable pharmacological interrogation of these enzymes in vivo. Chemical inhibition of AIG1 and ADTRP raised FAHFA levels demonstrating acute regulation of FAHFAs. In aggregate, the results establish AIG1 and ADTRP as the only endogenous FAHFA hydrolases known, and describe resources (mice, inhibitors) needed to elucidate the biochemical and physiological role of these exciting enzymes
AIG1 and ADTRP are endogenous hydrolases of fatty acid esters of hydroxy fatty acids (FAHFAs) in mice
Fatty acid esters of hydroxy fatty acids (FAHFAs) are a newly discovered class of signaling lipids with anti-inflammatory and anti-diabetic properties. However, the endogenous regulation of FAHFAs remains a pressing but unanswered question. Here, using MS-based FAHFA hydrolysis assays, LC-MS?based lipidomics analyses, and activity-based protein profiling, we found that androgen-induced gene 1 (AIG1) and androgen-dependent TFPI-regulating protein (ADTRP), two threonine hydrolases, control FAHFA levels in vivo in both genetic and pharmacologic mouse models. Tissues from mice lacking ADTRP (Adtrp-KO), or both AIG1 and ADTRP (DKO) had higher concentrations of FAHFAs particularly isomers with the ester bond at the 9(th) carbon due to decreased FAHFA hydrolysis activity. The levels of other lipid classes were unaltered indicating that AIG1 and ADTRP specifically hydrolyze FAHFAs. Complementing these genetic studies, we also identified a dual AIG1/ADTRP inhibitor, ABD-110207, which is active in vivo. Acute treatment of WT mice with ABD-110207 resulted in elevated FAHFA levels, further supporting the notion that AIG1 and ADTRP activity control endogenous FAHFA levels. However, loss of AIG1/ADTRP did not mimic the changes associated with pharmacologically administered FAHFAs on extent of upregulation of FAHFA levels, glucose tolerance, or insulin sensitivity in mice, indicating that therapeutic strategies should weigh more on FAHFA administration. Together, these findings identify AIG1 and ADTRP as the first endogenous FAHFA hydrolases identified and provide critical genetic and chemical tools for further characterization of these enzymes and endogenous FAHFAs to unravel their physiological functions and roles in health and disease
Recommended from our members
A class of anti-inflammatory lipids decrease with aging in the central nervous system.
Lipids contribute to the structure, development, and function of healthy brains. Dysregulated lipid metabolism is linked to aging and diseased brains. However, our understanding of lipid metabolism in aging brains remains limited. Here we examined the brain lipidome of mice across their lifespan using untargeted lipidomics. Co-expression network analysis highlighted a progressive decrease in 3-sulfogalactosyl diacylglycerols (SGDGs) and SGDG pathway members, including the potential degradation products lyso-SGDGs. SGDGs show an age-related decline specifically in the central nervous system and are associated with myelination. We also found that an SGDG dramatically suppresses LPS-induced gene expression and release of pro-inflammatory cytokines from macrophages and microglia by acting on the NF-ÎșB pathway. The detection of SGDGs in human and macaque brains establishes their evolutionary conservation. This work enhances interest in SGDGs regarding their roles in aging and inflammatory diseases and highlights the complexity of the brain lipidome and potential biological functions in aging